# Dr Lalchandani (NSE: DLCL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/DLCL · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹7 Cr, it ranks 3994th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.

Its return on equity was 4.2% in FY25. In Q4 FY24, the quarter ended 31 Mar 2024, revenue was ₹2 Cr and net profit ₹1 Cr, on a standalone basis. Promoters held 32.90% of the company as of 31 Mar 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹7 Cr |
| ROE | 4.2% (FY25) |
| ROCE | 3.6% (FY25) |
| Debt to equity | 0.41 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY24 | ₹2 Cr | — | ₹1 Cr | — | ₹1.63 |
| Q3 FY24 | — | — | — | — | — |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹4 Cr | ₹0 Cr |
| FY24 | ₹5 Cr | ₹1 Cr |
| FY23 | ₹5 Cr | −₹2 Cr |
| FY22 | ₹11 Cr | ₹1 Cr |
| FY21 | ₹10 Cr | ₹1 Cr |
| FY20 | ₹6 Cr | ₹0 Cr |

## Shareholding (31 Mar 2026)

- Promoters: 32.90%
- Non-institutions: 67.10%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Trinity League](https://app.pivotnow.in/stock/TRINITYLEA) | — | ₹8 Cr | — | — |
| [Adline Chem Lab](https://app.pivotnow.in/stock/ADLINE) | — | ₹8 Cr | — | — |
| [Unjha Formula](https://app.pivotnow.in/stock/UNJHAFOR) | — | ₹8 Cr | — | — |
| [Vivanza Bio](https://app.pivotnow.in/stock/VIVANZA) | — | ₹7 Cr | — | — |
| [DECIPHER LABS](https://app.pivotnow.in/stock/DECIPHER) | — | ₹6 Cr | — | — |
| [Evoq Remedies](https://app.pivotnow.in/stock/EVOQ) | — | ₹6 Cr | — | — |

## Questions and answers

### What is the market cap of Dr Lalchandani?

Dr Lalchandani's market capitalisation is ₹7 Cr (₹7 Cr) at the 22 Oct 2026 close, ranking 3994th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Dr Lalchandani?

Return on equity was 4.2% in FY25 and return on capital employed was 3.6% in FY25 (standalone figures).

### Is Dr Lalchandani a debt-free company?

No. Dr Lalchandani's debt-to-equity ratio was 0.41 in FY25, with total debt of ₹0 Cr.

### What were Dr Lalchandani's latest quarterly results?

For Q4 FY24 (quarter ended 31 Mar 2024), Dr Lalchandani reported revenue of ₹2 Cr and net profit of ₹1 Cr.

### What is the shareholding pattern of Dr Lalchandani?

As of 31 Mar 2026: promoters 32.90%, non-institutions 67.10%.

### Who are Dr Lalchandani's competitors?

The listed Pharma & Healthcare companies closest to Dr Lalchandani by market cap are Trinity League, Adline Chem Lab, Unjha Formula, Vivanza Bio, DECIPHER LABS and Evoq Remedies.

### Is Dr Lalchandani a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Dr Lalchandani's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DLCL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.